BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1484 related articles for article (PubMed ID: 26203136)

  • 1. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
    Chételat G; Fouquet M
    Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.
    Parent MJ; Zimmer ER; Shin M; Kang MS; Fonov VS; Mathieu A; Aliaga A; Kostikov A; Do Carmo S; Dea D; Poirier J; Soucy JP; Gauthier S; Cuello AC; Rosa-Neto P
    J Neurosci; 2017 Dec; 37(50):12263-12271. PubMed ID: 29097597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
    Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
    J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
    Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
    Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
    Risacher SL; Kim S; Nho K; Foroud T; Shen L; Petersen RC; Jack CR; Beckett LA; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
    Alzheimers Dement; 2015 Dec; 11(12):1417-1429. PubMed ID: 25960448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
    Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
    JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism.
    Benvenutto A; Giusiano B; Koric L; Gueriot C; Didic M; Felician O; Guye M; Guedj E; Ceccaldi M
    J Alzheimers Dis; 2018; 65(4):1147-1157. PubMed ID: 30124446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.
    Ghisays V; Goradia DD; Protas H; Bauer RJ; Devadas V; Tariot PN; Lowe VJ; Knopman DS; Petersen RC; Jack CR; Caselli RJ; Su Y; Chen K; Reiman EM
    Alzheimers Dement; 2020 Apr; 16(4):598-609. PubMed ID: 31831374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients.
    Zhou Y; Yu F; Duong TQ;
    J Magn Reson Imaging; 2015 Jan; 41(1):102-9. PubMed ID: 24382798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
    Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings.
    Jack CR; Wiste HJ; Weigand SD; Knopman DS; Mielke MM; Vemuri P; Lowe V; Senjem ML; Gunter JL; Reyes D; Machulda MM; Roberts R; Petersen RC
    Brain; 2015 Dec; 138(Pt 12):3747-59. PubMed ID: 26428666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
    Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S;
    Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study.
    Mosconi L; Rahman A; Diaz I; Wu X; Scheyer O; Hristov HW; Vallabhajosula S; Isaacson RS; de Leon MJ; Brinton RD
    PLoS One; 2018; 13(12):e0207885. PubMed ID: 30540774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.